VYNE Therapeutics Inc. (VYNE) News
Filter VYNE News Items
VYNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VYNE News From Around the Web
Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateTransformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024 BRIDGEWATER, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage bi |
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today an |
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 MillionTransformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the closing of its previously announced private placement financing (the “PIPE”). In the PIPE, VYNE received aggrega |
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 2024, followed by Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024Preclinical data and clinical programs to be discussed at |
VYNE Therapeutics Announces Private Placement of $88 MillionTransaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare |
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental VitiligoClinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts Clinical response and rapid onset of action suggest VYN201 has the potential to be the category leader in the treatment of nonsegmental vitiligo VYN201 is expected to advance into a Phase 2b c |
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceBRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will a |
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAnticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of indication selection in Q4 2023 and initiating a Phase 1 trial in Q1 2024 BRIDGEWATER, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceuti |
VYNE Therapeutics to Attend BIO International ConventionBRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that members of management will attend the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston, |
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateAnticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of an IND filing by year-end 2023 BRIDGEWATER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focu |